Neurocrine Biosciences Overview
Neurocrine Biosciences Target Price
Analysts' 12-month price predictions for NBIX.
Share Price
$136.66
Average Target Price
$177.00
29.5% upside
29.5% upside6 analysts in the last 4 months
High: $200 | Low: $160
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2024-05-28 | UBSAshwani Verma | $193 | 41.2% upside |  |
| 2024-05-13 | Evercore ISICory Kasimov | $175 | 28.1% upside | |
| 2024-05-02 | Canaccord GenuitySumant Kulkarni | $164 | 20% upside | |
| 2024-05-02 | H.C. WainwrightAndrew Fein | $160 | 17.1% upside | |
| 2024-04-23 | Wells FargoMohit Bansal | $170 | 24.4% upside | |
| 2024-03-12 | OppenheimerJay Olson | $200 | 46.3% upside | |
| 2023-02-03 | Morgan Stanley | $130 |  4.9% downside | |
| 2022-11-02 | H.C. WainwrightAndrew Fein | $140 | 2.4% upside | |
| 2022-11-02 | SVB SecuritiesMarc Goodman | $115 | 15.8% downside | |
| 2022-11-02 | Piper SandlerDavid Amsellem | $103 | 24.6% downside | |
| 2022-11-02 | Robert W. BairdBrian Skorney | $150 | 9.8% upside | |
| 2022-02-14 | H.C. WainwrightAndrew Fein | $140 | 2.4% upside | |
| 2022-02-11 | Raymond JamesDanielle Brill | $125 | 8.5% downside | |
| 2022-02-11 | Stifel NicolausPaul Matteis | $136 | 0.5% downside | |
| 2022-02-11 | Leerink PartnersMarc Goodman | $100 | 26.8% downside | |
| 2022-02-11 | Robert W. BairdBrian Skorney | $117 | 14.4% downside | |
| 2022-01-26 | Bank of America SecuritiesTazeen Ahmad | $127 | 7.1% downside | |
| 2022-01-20 | BarclaysCarter Gould | $100 | 26.8% downside | |
| 2021-12-08 | CitigroupNeena Bitritto-Garg | $129 | 5.6% downside | |
| 2021-11-02 | Cantor FitzgeraldCharles Duncan | $123 | 10% downside | |
| 2021-11-02 | Evercore ISIJoshua Schimmer | $130 | 4.9% downside | |
| 2021-08-06 | Canaccord GenuitySumant Kulkarni | $108 | 21% downside | |
| 2021-08-04 | WedbushLaura Chico | $112 | 18% downside | |